Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes
Trial shows different GLP-1 medications impact weight and blood sugar
A network meta-analysis evaluates GLP-1 receptor agonists in adolescents, identifying varying degrees of efficacy across weight, glucose, an…
New analysis of GLP-1 medications shows varying results for weight loss and blood sugar control in adolescents with obesity and type 2 diabe…
GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 Diabetes
GLP-1 medications show promise for heart health in diabetes
This meta-analysis of 37,393 patients with Type 2 Diabetes and myocardial infarction-defined populations found that GLP-1 receptor agonists …
A large review of over 37,000 patients suggests GLP-1 medications may lower heart failure risks for those with Type 2 Diabetes.
GLP-1 receptor agonists reduce apnea-hypopnea index by 15.28 events per hour in obstructive sleep apnea
GLP-1 receptor agonists show promise for obstructive sleep apnea
This network meta-analysis of 15 studies involving 1,877 participants found that GLP-1 receptor agonists significantly reduced the apnea-hyp…
New data suggests GLP-1 receptor agonists may reduce sleep apnea symptoms and improve oxygen levels in overweight or obese patients.
GLP-1 receptor agonists associated with favorable cardiovascular outcomes in adults with Type 2 Diabetes
GLP-1 medications show heart benefits for people with Type 2 Diabetes
This meta-analysis of randomized controlled trials included 97,173 adults with Type 2 diabetes to evaluate GLP-1-based therapies. The analys…
A large review of clinical trials shows that GLP-1 therapies can reduce major heart events and deaths in adults with Type 2 diabetes.
GLP-1 receptor agonists are an emerging research focus for metabolic and inflammatory pathways in Parkinson's disease
GLP-1 receptor agonists show promise for Parkinson's disease research
This bibliometric analysis of 282 articles identifies GLP-1 receptor agonists as a growing research area for Parkinson's disease. Key themes…
New research highlights how GLP-1 medications, often used for metabolic issues, are becoming a major focus in treating Parkinson's disease.
SGLT2 inhibitors and GLP-1 receptor agonists show similar MACE reduction in type 2 diabetes
Trial shows similar heart benefits for two diabetes medications
This systematic review and network meta-analysis compared SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular even…
Two common types of diabetes drugs both show significant reductions in major heart events for patients with a history of heart attacks.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
GLP-1 Receptor Agonists Associated with Reduced Cancer Risk in Patients with Type 2 Diabetes
GLP-1 medications may lower cancer risk for people with diabetes
This meta-analysis investigated the impact of GLP-1 receptor agonists on overall and site-specific cancer risks in adults with Type 2 Diabet…
New analysis suggests that GLP-1 receptor agonists might reduce the risk of several types of cancer in adults with Type 2 Diabetes.
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Shared molecular pathways and hub genes link endocrine disorders with periodontitis progression
Shared Molecular Pathways Link Endocrine Disorders and Periodontitis
This narrative review synthesizes the molecular mechanisms underlying the crosstalk between endocrine disorders and periodntis. It identifie…
New research identifies shared biological pathways that link endocrine disorders with gum disease, potentially changing how doctors treat bo…
GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
GLP-1 drugs help heart failure with preserved ejection fraction
This meta-analysis of 11,234 patients with heart failure (HFpEF and HFrEF) found that GLP-1 receptor agonists significantly reduced HF worse…
GLP-1 receptor agonists improve outcomes in heart failure with preserved ejection fraction but not in reduced ejection fraction, according t…